Therapeutic rationale to target highly expressed Aurora Kinase A conferring poor prognosis in cholangiocarcinoma

Keyphrases

• Poor Prognosis 100%
• Aurora Kinase A (AURKA) 100%
• Cholangiocarcinoma 100%
• Therapeutic Rationale 100%
• Alisertib 50%
• Antitumor Effect 30%
• Mitotic Spindle Checkpoint 30%
• Small Interfering RNA (siRNA) 20%
• CCK-8 Assay 10%
• Cell Growth 10%
• Gene Expression 10%
• MRNA Expression 10%
• Malignancy 10%
• Cell number 10%
• Poor Outcome 10%
• Interacting Proteins 10%
• Tumor Progression 10%
• Therapeutic Target 10%
• Apoptosis 10%
• Cell Cycle Arrest 10%
• Knockdown 10%
• Dysregulated 10%
• Tumor Growth 10%
• Specific Inhibitor 10%
• Poor Survival 10%
• Neoplasms 10%
• Chromosomal Instability 10%
• Xenograft Mouse Model 10%
• Rational Therapeutics 10%
• Xenograft Model 10%
• Kinesin 10%
• M Phase 10%
• Number Counts 10%
• Xenopus 10%
• Aurora Kinase Inhibitor 10%
• TPX2 10%
• Cholangiocarcinoma Cell Line 10%
• Mitotic Checkpoint 10%
• Human Cholangiocarcinoma 10%
• Targeted Protein 10%
• Public Dataset 10%
• Checkpoint Gene 10%
• Polo-like Kinase 1 10%
• Caspase 3/7 10%

Medicine and Dentistry

• Cholangiocarcinoma 100%
• Aurora A Kinase 100%
• Alisertib 45%
• Spindle Checkpoint 36%
• Small Interfering RNA 18%
• Tumor Progression 18%
• Xenograft 18%
• In Vitro 9%
• Neoplasm 9%
• Cholecystokinin Octapeptide 9%
• Cancer 9%
• Programmed Cell Death 9%
• Cell Growth 9%
• Protein Interaction 9%
• Cell Cycle M Phase 9%
• Chromosomal Instability 9%
• Cell Cycle Arrest 9%
• Cell Cycle Checkpoint 9%
• Cholangiocarcinoma Cell Line 9%
• Polo Like Kinase 1 9%
• Kinesin 9%
• Targeting Protein 9%
• Caspase 3 9%
• Messenger RNA 9%
• Therapeutic Target 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Bile Duct Carcinoma 100%
• Aurora A Kinase 100%
• Alisertib 45%
• Small Interfering RNA 18%
• Tumor Growth 18%
• Mouse Model 9%
• Xenopus 9%
• Kinesin 9%
• Cholecystokinin Octapeptide 9%
• Polo Like Kinase 1 9%
• Chromosomal Instability 9%
• Neoplasm 9%
• Caspase 3 9%
• Messenger RNA 9%